Carson Allaria Wealth Management, Ltd. Crispr Therapeutics Ag Transaction History
Carson Allaria Wealth Management, Ltd.
- $169 Million
- Q4 2024
A detailed history of Carson Allaria Wealth Management, Ltd. transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Carson Allaria Wealth Management, Ltd. holds 368 shares of CRSP stock, worth $18,558. This represents 0.01% of its overall portfolio holdings.
Number of Shares
368
Previous 368
-0.0%
Holding current value
$18,558
Previous $17,000
17.65%
% of portfolio
0.01%
Previous 0.01%
Shares
11 transactions
Others Institutions Holding CRSP
# of Institutions
484Shares Held
64.1MCall Options Held
1.64MPut Options Held
1.93M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl8.97MShares$453 Million3.09% of portfolio
-
Capital International Investors Los Angeles, CA8.74MShares$441 Million0.07% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.81MShares$192 Million0.09% of portfolio
-
Black Rock Inc. New York, NY2.78MShares$140 Million0.0% of portfolio
-
Nikko Asset Management Americas, Inc.2.75MShares$138 Million1.21% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $3.93B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....